高压氧联合依达拉奉和奥扎格雷治疗进展性脑梗死的疗效观察

目的总结分析高压氧联合依达拉奉和奥扎格雷治疗进展性脑梗死的疗效和安全性。方法选择2011年6月～2013年11月期间我院收治的56例进展性脑梗死患者,随机分为观察组和对照组各28例。观察组患者采取高压氧联合依达拉奉和奥扎格雷钠治疗,对照组患者仅采用依达拉奉联合奥扎格雷钠,于治疗前和治疗后分别对BI（日常生活活动能力）、NIHSS（神经功能缺损程度）和临床疗效进行评价。结果观察组临床疗效（96.43%）明显高于对照组,观察组NIHSS评分（7.5±1.6）明显低于对照组,而BI评分（78.5±3.7）明显高于对照组,差异具有统计学意义（P〈0.05）。结论高压氧联合依达拉奉和奥扎格雷钠治疗进展性脑梗死临床疗效较好,安全性更高,值得临床推广使用。

Efficacy of hyperbaric oxygen combined with the Ozagrel and Edaravone in treatment of progressive cerebral infraction

Objective To analyze the efficacy and safety of the therapy of hyperbaric oxygen combined with the Ozagrel and the Edaravone in treating progressive cerebral infraction. Methods A total of 56 progressive cerebral infraction hospitalized patients from June 2011 and November 2013 were randomly divided them into observation and the control group, each of 28 cases. The observation group received therapy of hyperbaric oxygen combined with the Ozagrel and the Edaravone while the control group only received the Ozagrel and the Edaravone. For the two groups, BI（capabilities of daily life）, NIHSS（neural function deficiency） and clinical efficacy were used to evaluate therapeutic effectiveness respectively before and after the treatment. Results The BI score（78.5±3.7） and the clinical effective rate（96.43%）of the observation group were remarkably higher than those of the control group. While the NIHSS score（7.5±1.6） was much lower. The differences between the two groups were statistically significant（P〈0.05）. Conclusion The hyperbaric oxygen combined with the Ozagreland the Edaravone are more effective and safer to be applied to the progressive cerebral infraction, which is worth being widely used in the clinical treatment.